Cenna Biosciences, Inc. is a privately-held biopharmaceutical company in La Jolla CA, focused on the discovery and development of novel drugs for the prevention and treatment of Alzheimer’s disease (AD). The Company was founded in 2006 to translate over a decade’s academic research at UC San Diego by the Founders. Founders became independent of UC San Diego in 2011. Disease-modifying therapies for Alzheimer’s disease are urgently needed. No existing technologies under development have been shown to delay disease progression or provide significant patient benefit. Cenna has a novel and different proprietary patented technology that arrests the underlying cause of the disease and that addresses previous failures by others. Preclinical studies are in progress with IND filing planned for 2021. Funding to date by Founders and NIH and other grants.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Peptide candidate mP8 and small molecule candidate A3
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):